

Mali

Tuberculosis profile

Population 2015

18 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.7 (0.99–2.5)	9.4 (5.6–14)
Mortality (HIV+TB only)	0.44 (0.28–0.64)	2.5 (1.6–3.7)
Incidence (includes HIV+TB)	10 (6.5–14)	57 (37–81)
Incidence (HIV+TB only)	1.4 (0.85–2)	7.7 (4.8–11)
Incidence (MDR/RR-TB)**	0.61 (0.14–1.1)	3.5 (0.8–6.3)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.6 (0.3–0.9)	3.1 (1.1–5.1)	3.7 (1.4–6)
Males	0.5 (0.3–0.71)	5.9 (4–7.7)	6.4 (4.3–8.4)
Total	1.1 (0.71–1.5)	8.9 (6.8–11)	10 (6.5–14)

TB case notifications, 2015

Total cases notified	7 015
Total new and relapse	6 732
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	60%
- % pulmonary	82%
- % bacteriologically confirmed among pulmonary	87%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	67% (47–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.22 (0.12–0.36)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	523	13%
- on antiretroviral therapy	465	89%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			250 (26–480)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance	2%	53%	381
MDR/RR-TB cases tested for resistance to second-line drugs			10
Laboratory-confirmed cases		MDR/RR-TB: 30, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 30, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	73%	5 177
Previously treated cases, excluding relapse, registered in 2014	70%	789
HIV-positive TB cases, all types, registered in 2014	57%	240
MDR/RR-TB cases started on second-line treatment in 2013	42%	12
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	3.4% (3.1–3.7)

TB financing, 2016

National TB budget (US\$ millions)


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically